Tau protein Inhibitors
1 drugsAbout Tau protein
Tau protein, a microtubule-associated protein primarily in neurons, stabilizes microtubules essential for cellular structure and transport. In neurodegenerative diseases, Tau becomes hyperphosphorylated and misfolded, forming neurofibrillary tangles. These tangles are a hallmark of diseases affecting the central nervous system (CNS).
Tau's role in neurodegenerative disease pathology makes it a therapeutic target for CNS disorders. However, there is currently no genetic evidence directly linking Tau to specific diseases in this dataset. Targeting Tau aggregation or phosphorylation could potentially slow or reverse disease progression.
Currently, one FDA-approved drug, TAUVID, targets Tau protein for CNS indications. TAUVID, a small molecule, was first approved in 2020 by AVID Radiopharmaceuticals Inc.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Substance Use Disorders with only 1 trials.
Top Tau protein Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting Tau.
Low competition presents an opportunity for new entrants, but also indicates potential challenges in the target's tractability.
Tau protein Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Tau protein, using small molecule modality.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing treatments.
Tau protein Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Tau protein Drug Approval Timeline (2020 - 2020)
TAUVID was the first and most recent drug approved in 2020, creating a short approval span of 1 year.
The recent approval suggests renewed interest in Tau as a target, but the lack of subsequent approvals indicates potential hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting Tau protein.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities